Fertility After Long-Term Targeted Therapy: — What the Data Shows

Yes, and this is one of the better-studied areas in the TKI-fertility space. ELN guidance for CML includes a pathway for patients who want to attempt pregnancy: achieving and sustaining deep molecular response over at least two years is the standard pre-condition before stopping is considered. Planned pregnancies after supervised TKI stops have been reported in the literature, though molecular relapse during the treatment-free period is common and intensive monitoring is required throughout. This is a decision that needs your oncologist, not a general answer.

The honest answer is that we do not yet know with certainty. For men, sperm parameter changes appear to be at least partially reversible after stopping. For women, the picture is less clear — reduced ovarian reserve may not recover fully, and age compounds the effect because the window for preserving eggs narrows with time. This is one reason ASCO and ESMO guidance recommends having the fertility conversation at or before diagnosis, not years into treatment when the opportunity may have narrowed.

Possibly, but it is not straightforward. Egg freezing requires hormonal stimulation over several weeks, and for some TKIs there is uncertainty about whether it is safe to continue the drug through that process. A brief supervised pause may be considered. The feasibility depends on your specific drug, your response to treatment, and your cancer type. A reproductive oncology specialist working alongside your oncologist is the right team to advise you — not a standard fertility clinic without access to your oncology records.

Deep molecular response — often called MR4 or MR4.5 in CML — means the cancer signal in your blood has dropped to a very low level, detected only by sensitive PCR testing. For CML, achieving this level of response and sustaining it for at least two years is the threshold ELN sets before stopping a TKI for pregnancy is considered. The rationale is that deeper, sustained responses are associated with a higher probability of staying in remission off treatment. A borderline or fluctuating response does not meet that threshold.

Tell them as early as you can and be specific: that you want to have children, within what timeframe, and whether your partner is involved in the decision. Ask directly whether your current response would make you a candidate for a planned stop, what monitoring would be needed, and what the relapse risk looks like in your case. Ask also whether fertility preservation has been discussed and whether it is still possible. Bringing a written list of questions helps, because these conversations are hard to remember accurately afterwards.

Yes, and meaningfully so. Different TKIs have different half-lives, different teratogenic risk profiles, and different evidence bases for their fertility effects. The washout interval your team recommends, the monitoring approach during a treatment-free period, and the evidence on fertility recovery will all vary by drug. This is why a generic answer — even from a reputable source — does not substitute for advice specific to the TKI you are taking. If your oncologist is not familiar with the fertility literature for your drug, a second opinion from a specialist centre is reasonable to request.